Background Adrenocortical carcinoma (ACC) is a rare endocrine carcinoma with poor 5-year survival rates of < 40%. According to the literature, ACC is rarely an incidental imaging finding. However, presentation, treatment and outcome may differ in modern series. Design and methods We studied all patients (n = 47, four children) from a single centre during years 2002-2018. We reevaluated radiologic and histopathological findings and assessed treatments and outcome. We searched for possible TP53 gene defects and assessed nationwide incidence of ACC. Results In adults, incidental radiologic finding led to diagnosis in 79% at median age of 61 years. ENSAT stage I, II, III and IV was 19%, 40%, 19% and 21%, respectively. Nonenhanced CT demonstrated > 20 Hounsfield Units (HU) for all tumours (median 34 (21-45)), median size 92 mm , Ki67 17% (1-40%), Weiss score 7 (4-9) and Helsinki score 24 (4-48). ACC was more often found in the left than the right adrenal (p < 0.05). One child had Beckwith-Wiedemann and one a TP53 mutation. In adults, the primary tumour was resected in 88 and 79% received adjuvant mitotane therapy. Median hospital stay was significantly shorter in the laparoscopic vs. open surgery group (4 (3-7) vs. 8 (5-38) days, respectively; p < 0.001). In 3/4 patients, prolonged remission of > 5 to > 10 years was achieved after repeated surgery of metastases. Overall 5-year survival was 67%, and 96% vs. 26% for ENSAT stage I-II vs. III-IV (p < 0.0001). ENSAT stage and Ki67 predicted survival, type of surgery did not. Mitotane associated with better survival. Conclusions Contemporary ACC predominantly presents as an incidental imaging finding, characterised by HU > 20 on nonenhanced CT but variable tumour size (20-196 mm). Malignancy cannot be ruled out by small tumour size only. The 5-year survival of 96% in ENSAT stage I-III compares favourably to previous studies.
Introduction
Adrenocortical carcinoma (ACC) is a rare and aggressive endocrine malignancy that can occur at any age. In adults, the estimated incidence of ACC is one per million per year [1, 2] . Most series report 5-year survivals < 40% [1, [3] [4] [5] [6] [7] [8] [9] [10] [11] . In children < 3 years, 5-year disease-free survival after total resection is 80%, while in those > 13 years survival is 40%, similar to that in adults [2, 12] . Disease stage, best defined by the European Network for the Study of Adrenal Tumours (ENSAT stage), radical surgery, age, Ki67 and Helsinki Score seem to predict survival [2, 3, [13] [14] [15] . Adjuvant mitotane is recommended in adult patients with high risk of recurrence [16, 17] and mitotane monotherapy or combined mitotane and etoposide-doxorubicin cisplatin treatment for advanced disease [18, 19] .
Previously, 10-15% of ACCs have presented as incidental imaging findings [20, 21] , while reported prevalence of ACC among adrenal incidentalomas has varied between 1-11% [22] . However, incidentally discovered asymptomatic adrenal masses are getting more common due to increasing use of imaging [22, 23] . We hypothesised that presentation and outcome of ACC may differ in modern compared to old series. We here report data on presentation, treatment and outcome in a contemporary series, including all patients from a single centre diagnosed in 2002 to 2018, and nationwide incidence of ACC in 2001-2015.
Subjects and methods

Patient population
Patients were identified from the Helsinki University Hospital pathology registry and electronic patient records using ICD-10 codes C74.0 and 74.9. All cases (Weiss score ≥ 4 [24, 25] ) diagnosed between 1 January 2002 and 27 April 2018 were included.
Histopathological evaluation
Two endocrine pathologists (M.P., J.A.) re-evaluated all tumours and determined Ki67, Weiss and Helsinki scores [13] . One tumour with Weiss score 3 was excluded.
Radiologic evaluation
Preoperative computed tomography (CT) images were reevaluated with the Agfa Impax PACS software by an abdominal radiology specialist (H.P.). Tumour size was defined as largest axial plane diameter. Presence or absence of tumour thrombus or distant metastases was evaluated from contrast-enhanced images. Hounsfield units (HU) were measured from noncontrast images by placing a single round region of interest (ROI) on the tumour. The ROI covered the largest possible part of the tumour plane, avoiding necrosis, haemorrhage and calcifications.
Data collection
Data on clinical presentation, laboratory measurements, tumour characteristics, surgery, histopathology and adjuvant treatments during years 2002 to 2018 were collected from our electronic patient records. All laboratory tests, including germline gene mutation testing, were performed with in house methods in the Helsinki University Hospital Central Laboratory, HUSLAB. We used ENSAT Criteria (stage I = tumour diameter ≤ 5 cm, stage II tumour diameter > 5 cm, stage III = infiltration of neighbouring structures, venous tumour thrombosis in caval or renal vein, or positive lymph nodes, stage IV = distant metastases) [3] . We registered recurrences and deaths. We retrieved nationwide number of ACC cases and age standardised 5-year incidences from the Finnish Cancer Registry; www.ca ncersociety.fi.
The study protocol was approved by the board review of the Abdominal Centre, Helsinki University Hospital.
Statistical analysis
Data is presented as median (interquartile range, IQR, or range) for continuous variables. For categorical data, rates and proportions were calculated. Fisher exact test was used for calculation of differences between groups. Mean ranks between groups were compared with Mann-Whitney-U-test. Median survival was calculated according to Kaplan-Meier and predictors of survival with Cox proportional hazards regression analyses. All reported p-values are two-sided. pvalues < 0.05 (two-tailed) were considered statistically significant. Ki-67 was grouped in three categories: (1) 1-9%, (2) 10-19% and (3) ≥ 20%. Calculations were performed with SPSS25.
Results
Patient characteristics
Altogether 47 patients, 4 (9%) being children, were diagnosed with ACC. In adults, median age at diagnosis was 61 years (IQR 53-66), 25 (58%) were female and median follow-up was 35 months (IQR 8-89). At presentation, 15/ 42 (36%) had non-specific abdominal pain and 6/42 (14%) bruises; 5/25 (24%) women had hirsutism and the youngest woman (20 years) menstrual disturbances. Eight patients had potassium concentrations < 3.5 mmol/l ( < 3.0 mmol/l in 7, lowest 1.6 mmol/l). Sixty-three percent had biochemically verified adrenal hormone excess. Isolated hypercortisolism (41%) was most common, followed by excess cosecretion of cortisol and androgens (22%), isolated hyperandrogenism (19%), co-secretion of aldosterone and cortisol and aldosterone (11%) and isolated aldosterone excess (7%).
Characteristics of children with adrenocortical carcinoma
Characteristics of children with ACC are given in Table 1 (Table 1) .
Time between diagnosis and surgery was 7, 8 and 16 days in symptomatic patients and 51 days for the nonsymptomatic child. Three children were discharged on the fourth postoperative day, postoperative recovery of patient 1 included 2 days in ICU, 49 days in the paediatric ward and chemotherapy on the 52nd postoperative day. All children received 4-6 cycles of adjuvant etoposidecisplatin therapy. At 7.9 years (1.5-11.8 years) of followup, all children are in remission and have reached the developmental milestones according to age. So far, children with Beckwith-Wiedemann and Li-Fraumeni syndrome have not displayed other manifestations. Patient 4 predictably developed precocious central puberty and received GnRH-analogue therapy from 6.2 to 13.8 years of age (Fig. 1a) . After cessation of GnRH-therapy, puberty proceeded normally and he reached his adult target height.
TP53 and other gene defects and cancers in patients with adrenocortical carcinoma
Gene defects in children are presented in Table 1 . Ten adult patients (age < 20 years (n = 3), concomitant other cancers (follicular lymphoma, earlier ACC and breast cancer, lung adenocarcinoma, prostate cancer (n = 4)) or strong family history of cancer (n = 3)) were screened for germline TP53 gene mutations, all were negative. 
Radiologic characteristics of adrenocortical carcinoma and ENSAT staging in adult patients
Median tumour size was 91.5 mm (IQR 52.3-133.0) with no significant gender difference (p = 0.98) ( Table 2) Table 2 ). There was no significant difference in the proportion of men and women in ENSAT groups I-II compared to III-IV (p = 1.0).
Surgery in adult patients with adrenocortical carcinoma
Surgical characteristics are given in Table 3 . The primary tumour was operated in 38 (88%) patients. One tumour was Table 3 ). The laparoscopic group included successful surgery of four tumours ranging from 60-100 mm. Additional organs (eight kidneys, five spleens, three partial resections of pancreas, one partial liver resection) were resected in ten operations.
Surgery was significantly more common in ENSAT stage I-II compared to III-IV (25/25 (100%) vs. 12/17 (71%), respectively, p = 0.007), and open surgery (laparotomy or conversion) more common than laparoscopic surgery in ENSAT III-IV compared to I-II (p = 0.002). Median tumour size was smaller in the laparoscopic compared to the open surgery group (Table 3 , p < 0.0001). Rupture of tumour capsule occurred in four surgeries, and was unrelated to the surgical method (p = 1.0).
There was no surgical mortality, but seven (16%) patients had postoperative complications, graded according to Clavien-Dindo [26] (Table 3) . Infections were most common (sepsis (n = 2), abscess (n = 2), pneumonia (n = 2), wound infection (n = 2), infection of uncertain origin (n = 1)). Injury of diaphragm caused herniation of the gastric fundus in one patient, requiring surgical correction. The incidence of complications was unrelated to the surgical method (open surgery vs. laparoscopy, p = 0.11). Median hospital stay was significantly longer in the open compared to laparoscopic surgery group (median 8 compared to 4 days, respectively; p < 0.0001).
Surgery in metastatic disease
Metastases were resected in four patients (lung metastases, lung metastases followed by three additional resections of lung metastases, lung metastases followed by resection of liver metastases, resection of lymph node metastasis). Two of these patients have achieved sustained remission of > 5 years, and another patient is alive with > 10 years survival and unremarkable CT in November 2018. Fig. 1 a Growth chart demonstrates accelerated growth in a 5-year-old boy with androgen secreting ACC. Hyperandrogenism resulted in advanced bone age (12.8 years) and subsequent precocious central puberty that was treated with GnRH-analogue therapy from 6.2 to 13.8 years of age. b Growth chart of a 0.3-year-old boy with cortisol secreting ACC causing weight gain and decreased height velocity 
Systemic treatments
Data on systemic treatments is given in Table 4 . Thirty-four (79%) patients received adjuvant mitotane therapy. Twentytwo of them belonged to ENSAT stage I-II and 11 to III-IV. All except one fulfilled the indications for mitotane treatment as suggested by Fassnacht et al. [27] . Administration of mitotane therapy was not related to ENSAT stage (p = 0.12). Target concentrations were reached in 18 (60%) patients in 250 days (78-1055) with a cumulative dose of 870 g (169-2334). Median duration of mitotane therapy was 896 days (37-2786). Side-effects were common (Table 5) and treatment was discontinued in 11 (32%) patients because of liver toxicity, gastrointestinal and neurocognitive side-effects (Table 5) . Ten patients received other systemic treatments, including etoposide-doxorubicin-cisplatin (EDP), carboplatin and streptozocin. Two patients achived complete response with sustained remission of > 5 years (one (ENSAT II) treated with mitotane and carboplatin, and one (ENSAT III) with mitotane and EDP combination therapy). Five patients received palliative radioherapy for metastases. Surgical resection, mitotane and other systemic treatment 8 19 Mitotane and other systemic treatment 2 5
Systemic treatment other than mitotane 2 5
Only palliative treatment 1 2
Survival
Five-year overall survival was 67% and, for ENSAT I, II, III and IV 100%, 93%, 60% and 11% respectively. The difference between ENSAT I-II vs. III-IV was 96% vs. 26%, respectively (p < 0.0001; 
Discussion
We report on a modern series of ACC, including all patients diagnosed at a single centre in years 2002-2018 and demonstrate that almost 80% nowadays present as asymptomatic incidentally discovered adrenal masses, and that on nonenhanced CT, HU was > 20 for all cases. This is in contrast to the literature, reporting incidental tumour finding in 10-15% of ACC, probably reflecting historical cases diagnosed in 1970-1990 [2, 20, 21] . Adrenal incidentalomas are common due to frequent imaging, the majority representing nonfunctioning adrenal adenomas for which neither surgery nor further imaging is needed [22] . Most adrenal adenomas are homogenous, < 4 cm large and lipid rich, and thus characterised by < 10 HU on nonenhanced CT [22, 28] . ACC and pheochromocytoma are the most important differential diagnoses and must be adequately diagnosed. A German study concluded that HU > 21 provides the best accuracy for diagnosing ACC (96% sensitivity, 80% specificity), however, Weiss scores were not reported [29] . Radiological features of early, small ACCs are rarely reported in the literature [30] and may easily be overlooked. The smallest ACCs of 2 and 2.5 cm in the present study were incidental findings on chest and trauma CT (a 59-year old woman, a 22-year old male), with noncontrast HUs of 34 and 40, and Weiss scores of 7 and 4, respectively. Ozsari et al. [31] reported substantial diagnostic delay of up to 89 months in ACC, in a series of patients with incidentally found adrenal tumours characterised by a high noncontrast HU and small ( < 4 cm) tumour size. The authors concluded that presumed benign nature of pre-existing masses based on size is the main reason for delayed ACC diagnosis. Data on the incidence of ACC is scarce. We assessed nationwide incidence in 2001-2015 and it is close to the previously reported 1 per million persons annually. A Dutch study reported a declining incidence trend [1] , while a recent report from the SEER database, U.S.A, reported increasing trends (597 cases in 1995-2004 compared to 933 cases in [2005] [2006] [2007] [2008] [2009] [2010] [2011] [2012] [2013] [2014] [32] .
Open surgery is considered the standard approach for large tumours with high suspicion of or confirmed ACC, at Fig. 2 Comparison of overall survival rates of ENSAT stage I-II and III-IV patients using Kaplan-Meier method least for tumours demonstrating local invasion. The recent ESE Clinical Practice Guidelines on ACC [33] suggest laparoscopic surgery for tumours < 6 cm without evidence of invasion. In the present study, four adult patients with tumour diameter 6-10 cm, not characterised by invasion successfully underwent laparoscopic surgery. Our results indicate that laparoscopic surgery can be applied in selected cases also for tumours > 6 cm. Importantly, laparoscopic surgery enabled significantly shorter hospitalisation compared to open surgery, and did not impair survival. Two cases were converted because the tumour obstructed the view and one because of adherence to the pancreas. Surgery for ACC, especially laparoscopic, must be reserved for high-volume centres [34, 35] . In 2016 and 2017, the number of laparoscopic adrenalectomies performed at the Helsinki University Hospital was 39 and 51, respectively. In advanced ACC, survival is still very poor, and metastatic ACC is characterised by higher mutation rate and tumour heterogeneity than the primary tumours [36] . As medical treatment options are limited, surgery of metastases should be considered in selected cases. In the present study, four patients underwent resection of metastases, and three clearly benefited, two (ENSAT I and IV; lung metastases, lung metastasis followed by liver metastasis) are in remission (survival > 6 and > 9 years), the third patient (ENSAT II; recurring lung metastases) is alive with prolonged survival of > 10 years. Of ten patients undergoing further systemic therapy, one treated with mitotane and carboplatin and one with mitotane and EDP (combination therapy, ENSAT stage II and III, respectively) achieved complete response and are alive ( > 5 years).
In the present cohort, 5-year survival rates were 100%, 93%, 60% for ENSAT I, II and III, respectively. This compares favourably to older cohorts [10, [37] [38] [39] [40] and probably reflects the high percentage of patients undergoing surgery (88%) and mitotane therapy (79%). However, for ENSAT stage IV, 5-year survival remains poor (11%). ENSAT stage and Ki67 > 19% predicted survival and, as previously reported, mitotane therapy was associated with better survival [7, 33] . Berruti et al. [41] demonstrated that overt clinical hypercortisolism was a negative prognostic factor in ACC. In the present study, 41% had biochemically verified hypercortisolism and this did not predict outcome. The study by Berruti et al. was much larger than the present one, in addition, hypercortisolism was defined differently. Currently, the impact of cortisol secretion on survival in ACC remains uncertain [2] .
Mitotane frequently causes side-effects and these were quite common (91%) also in the present study. Mitotane therapy associates with better survival, it is thus important to tailor the treatment according to best practice, including drug concentration monitoring and adequate replacement with rather high hydrocortisone doses, as well as thyroxine and testosterone [42] .
As ACC is a very rare cancer, the sample size of the present study was small and this is a clear limitation. Larger series are needed to confirm some of the findings of the present study, such as percentage of cases presenting as incidental cases in other modern series, better characteristics of small ACCs, the role of laparoscopic surgery and surgery of metastases. It is unclear why most of the ACCs were found in the left and not the right adrenal.
In conclusion, contemporary ACC predominantly presents as an incidental imaging finding, characterised by HU > 20 on nonenhanced CT but variable tumour size (20-196 mm) . Malignancy cannot be ruled out by small tumour size only. The 5-year survival of 96% in ENSAT stage I-III compares favourably to previous studies.
Funding Open access funding provided by University of Helsinki including Helsinki University Central Hospital. This study was funded by the Helsinki University Hospital Research Funds (TYH2016129 and TYH2017138 to C. Schalin-Jäntti) and Finska Läkaresällskapet (to C. Schalin-Jäntti and C. Haglund).
Compliance with ethical standards
Conflict of interest The authors declare that they have no conflict of interest.
Informed consent Authorisation to perform this retrospective study without individual consent was granted by the Scientific Board of the Abdominal Centre, Helsinki University Hospital (HUS §45, 269/ 2017).
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://crea tivecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
